Base de dados : MEDLINE
Pesquisa : E02.815.150 [Categoria DeCS]
Referências encontradas : 17709 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1771 ir para página                         

  1 / 17709 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463163
[Au] Autor:Connor MJ; Tringale K; Moiseenko V; Marshall DC; Moore K; Cervino L; Atwood T; Brown D; Mundt AJ; Pawlicki T; Recht A; Hattangadi-Gluth JA
[Ad] Endereço:Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California; University of California Irvine School of Medicine, Irvine, California.
[Ti] Título:Medical Device Recalls in Radiation Oncology: Analysis of US Food and Drug Administration Data, 2002-2015.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):438-446, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To analyze all recalls involving radiation oncology devices (RODs) from the US Food and Drug Administration (FDA)'s recall database, comparing these with non-radiation oncology device recalls to identify discipline-specific trends that may inform improvements in device safety. METHODS AND MATERIALS: Recall data on RODs from 2002 to 2015 were sorted into 4 product categories (external beam, brachytherapy, planning systems, and simulation systems). Outcomes included determined cause of recall, recall class (severity), quantity in commerce, time until recall termination (date FDA determines recall is complete), and time since 510(k) approval. Descriptive statistics were performed with linear regression of time-series data. Results for RODs were compared with those for other devices by Pearson χ test for categorical data and 2-sample Kolmogorov-Smirnov test for distributions. RESULTS: There were 502 ROD recalls and 9534 other class II device recalls during 2002 to 2015. Most recalls were for external beam devices (66.7%) and planning systems (22.9%), and recall events peaked in 2011. Radiation oncology devices differed significantly from other devices in all recall outcomes (P≤.04). Recall cause was commonly software related (49% vs 10% for other devices). Recall severity was more often moderate among RODs (97.6% vs 87.2%) instead of severe (0.2% vs 4.4%; P<.001). Time from 510(k) market approval to recall was shorter among RODs (P<.001) and progressively shortened over time. Radiation oncology devices had fewer recalled devices in commerce than other devices (P<.001). CONCLUSIONS: Compared with other class II devices, RODs experience recalls sooner after market approval and are trending sooner still. Most of these recalls were moderate in severity, and software issues are prevalent. Comprehensive analysis of recall data can identify areas for device improvement, such as better system design among RODs.
[Mh] Termos MeSH primário: Recall de Dispositivo Médico
Radioterapia (Especialidade)/instrumentação
Software/estatística & dados numéricos
United States Food and Drug Administration/estatística & dados numéricos
[Mh] Termos MeSH secundário: Braquiterapia/instrumentação
Distribuição de Qui-Quadrado
Bases de Dados Factuais/estatística & dados numéricos
Equipamentos e Provisões/classificação
Equipamentos e Provisões/provisão & distribuição
Modelos Lineares
Vigilância de Produtos Comercializados/normas
Vigilância de Produtos Comercializados/estatística & dados numéricos
Radioterapia (Especialidade)/estatística & dados numéricos
Planejamento da Radioterapia Assistida por Computador/instrumentação
Planejamento da Radioterapia Assistida por Computador/estatística & dados numéricos
Estatísticas não Paramétricas
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  2 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29206372
[Au] Autor:Zequi SC
[Ad] Endereço:Editor Associado do International Braz J Urol.
[Ti] Título:Focal therapy will be the next step on prostate cancer management? | Opinion: Yes.
[So] Source:Int Braz J Urol;43(6):1013-1016, 2017 Nov-Dec.
[Is] ISSN:1677-6119
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Mh] Termos MeSH primário: Neoplasias da Próstata/cirurgia
[Mh] Termos MeSH secundário: Braquiterapia
Seres Humanos
Masculino
Recidiva Local de Neoplasia
Antígeno Prostático Específico
Prostatectomia/métodos
Neoplasias da Próstata/patologia
Neoplasias da Próstata/radioterapia
Medição de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1590/S1677-5538.IBJU.2017.06.02


  3 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463154
[Au] Autor:Chargari C; Haie-Meder C; Guérin F; Minard-Colin V; de Lambert G; Mazeron R; Escande A; Marsolat F; Dumas I; Deutsch E; Valteau-Couanet D; Audry G; Oberlin O; Martelli H
[Ad] Endereço:Brachytherapy Unit, Department of Radiotherapy, Gustave Roussy, Villejuif, France; Institut de Recherche Biomédicale des Armées, Bretigny-sur-Orge, France; French Military Health Service Academy, Ecole du Val-de-Grâce, Paris, France. Electronic address: cyrus.chargari@gustaveroussy.fr.
[Ti] Título:Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):352-359, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To report the results of a conservative strategy based on partial surgery combined with brachytherapy in a prospective cohort of children with bladder-prostate rhabdomyosarcoma (BP RMS). METHODS AND MATERIALS: We prospectively documented the outcome of children treated in our department between 1991 and 2015 for BP RMS and undergoing a multimodal approach combining conservative surgery (partial cystectomy and/or partial prostatectomy) and perioperative interstitial low-dose-rate or pulse-dose-rate brachytherapy. Before brachytherapy, children had received chemotherapy with modalities depending on their risk group of treatment. RESULTS: A total of 100 patients were identified, with a median age of 28 months (range, 5.6 months-14 years). According to the Intergroup Rhabdomyosarcoma Study (IRS) group, 84 were IRS-III, and 12 were IRS-IV tumors. Four patients were treated at relapse. The median number of chemotherapy cycles before local therapy was 6 (range, 4-13). After surgery, 63 patients had a macroscopic tumor residuum. Five patients underwent a brachytherapy boost before pelvic external beam radiation therapy because of nodal involvement, and 95 had exclusive brachytherapy. Median follow-up was 64 months (range, 6 months-24.5 years). Five-year disease-free and overall survival rates were 84% (95% confidence interval 80%-88%) and 91% (95% confidence interval 87%-95%), respectively. At last follow-up most survivors presented with only mild to moderate genitourinary sequelae and a normal diurnal urinary continence. Five patients required a secondary total cystectomy: 3 for a nonfunctional bladder and 2 for relapse. CONCLUSION: Brachytherapy is effective as part of a conservative strategy for BP RMS, with a relatively low delayed toxicity as compared with previously published studies using external beam radiation therapy. Longer follow-up is required to ensure that the functional results are maintained over time.
[Mh] Termos MeSH primário: Braquiterapia/métodos
Tratamento Conservador/métodos
Neoplasias da Próstata/radioterapia
Neoplasias da Próstata/cirurgia
Rabdomiossarcoma/radioterapia
Rabdomiossarcoma/cirurgia
Neoplasias da Bexiga Urinária/radioterapia
Neoplasias da Bexiga Urinária/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Antineoplásicos/uso terapêutico
Braquiterapia/efeitos adversos
Criança
Pré-Escolar
Terapia Combinada/métodos
Intervalos de Confiança
Tratamento Conservador/efeitos adversos
Cistectomia/efeitos adversos
Cistectomia/métodos
Cistectomia/estatística & dados numéricos
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Lactente
Masculino
Neoplasia Residual
Estudos Prospectivos
Prostatectomia/efeitos adversos
Prostatectomia/métodos
Prostatectomia/estatística & dados numéricos
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/mortalidade
Rabdomiossarcoma/tratamento farmacológico
Rabdomiossarcoma/mortalidade
Fatores de Tempo
Resultado do Tratamento
Neoplasias da Bexiga Urinária/tratamento farmacológico
Neoplasias da Bexiga Urinária/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  4 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463150
[Au] Autor:Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; Michalski JM; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium
[Ad] Endereço:Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: hiramgay@wustl.edu.
[Ti] Título:External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):304-317, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer. METHODS AND MATERIALS: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level. RESULTS: For subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively. CONCLUSIONS: Compared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/efeitos adversos
Braquiterapia/efeitos adversos
Terapia Neoadjuvante/efeitos adversos
Orgasmo
Ereção Peniana
Neoplasias da Próstata/terapia
Qualidade de Vida
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/uso terapêutico
Peso Corporal/efeitos dos fármacos
Peso Corporal/efeitos da radiação
Braquiterapia/métodos
Braquiterapia/estatística & dados numéricos
Mama/efeitos dos fármacos
Mama/efeitos da radiação
Distribuição de Qui-Quadrado
Terapia Combinada/efeitos adversos
Terapia Combinada/métodos
Terapia Combinada/estatística & dados numéricos
Depressão/etiologia
Disfunção Erétil/etiologia
Fadiga/etiologia
Fogachos/etiologia
Seres Humanos
Masculino
Meia-Idade
Terapia Neoadjuvante/métodos
Terapia Neoadjuvante/estatística & dados numéricos
Orgasmo/efeitos dos fármacos
Orgasmo/efeitos da radiação
Ereção Peniana/efeitos dos fármacos
Ereção Peniana/efeitos da radiação
Estudos Prospectivos
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/patologia
Inquéritos e Questionários
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Androgen Antagonists); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463152
[Au] Autor:Yang DD; Muralidhar V; Mahal BA; Labe SA; Nezolosky MD; Vastola ME; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
[Ad] Endereço:Harvard Medical School, Boston, Massachusetts.
[Ti] Título:National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):338-343, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Androgen deprivation therapy (ADT) is not recommended for low-risk prostate cancer because of its lack of benefit and potential for harm. We evaluated the incidence and predictors of ADT use in low-risk disease. METHODS AND MATERIALS: Using the National Cancer Database, we identified 197,957 patients with low-risk prostate cancer (Gleason score of 3 + 3 = 6, prostate-specific antigen level <10 ng/mL, and cT1-T2a) diagnosed from 2004 to 2012 with complete demographic and treatment information. We used multiple logistic regression to evaluate predictors of ADT use and Cox regression to examine its association with all-cause mortality. RESULTS: Overall ADT use decreased from 17.6% in 2004 to 3.5% in 2012. In 2012, 11.5% of low-risk brachytherapy patients and 7.6% of external beam radiation therapy patients received ADT. Among 82,352 irradiation-managed patients, predictors of ADT use included treatment in a community versus academic cancer program (adjusted odds ratio [AOR], 1.60; 95% confidence interval [CI], 1.50-1.71; P<.001; incidence, 14.0% vs 6.0% in 2012); treatment in the South (AOR, 1.51), Midwest (AOR, 1.81), or Northeast (AOR, 1.90) versus West (P<.001); and brachytherapy use versus external beam radiation therapy (AOR, 1.32; 95% CI, 1.27-1.37; P<.001). Among 25,196 patients who did not receive local therapy, predictors of primary ADT use included a Charlson-Deyo comorbidity score of ≥2 versus 0 (AOR, 1.42; 95% CI, 1.06-1.91; P=.018); treatment in a community versus academic cancer program (AOR, 1.61; 95% CI, 1.37-1.90; P<.001); and treatment in the South (AOR, 1.26), Midwest (AOR, 1.52), or Northeast (AOR, 1.28) versus West (P≤.008). Primary ADT use was associated with increased all-cause mortality in patients who did not receive local therapy (adjusted hazard ratio, 1.28; 95% CI, 1.14-1.43; P<.001) after adjustment for age and comorbidity. CONCLUSIONS: ADT use in low-risk prostate cancer has declined nationally but may remain an issue of concern in certain populations and regions.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Centros Médicos Acadêmicos/estatística & dados numéricos
Centros Médicos Acadêmicos/tendências
Adulto
Idoso
Idoso de 80 Anos ou mais
Braquiterapia/utilização
Institutos de Câncer/estatística & dados numéricos
Institutos de Câncer/tendências
Centros Comunitários de Saúde/estatística & dados numéricos
Centros Comunitários de Saúde/tendências
Crioterapia/utilização
Bases de Dados Factuais/estatística & dados numéricos
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
National Cancer Institute (U.S.)/estatística & dados numéricos
Gradação de Tumores
Modelos de Riscos Proporcionais
Prostatectomia/utilização
Neoplasias da Próstata/epidemiologia
Neoplasias da Próstata/radioterapia
Neoplasias da Próstata/cirurgia
Radioterapia/utilização
Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androgen Antagonists)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  6 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463151
[Au] Autor:O'Callaghan ME; Raymond E; Campbell JM; Vincent AD; Beckmann K; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti K
[Ad] Endereço:South Australian Prostate Cancer Clinical Outcomes Collaborative; Freemasons Foundation Centre for Men's Health, University of Adelaide; Urology Unit, Repatriation General Hospital, SA Health; Flinders Centre for Innovation in Cancer. Electronic address: elspeth.raymond@health.sa.gov.au.
[Ti] Título:Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):318-337, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To identify, through a systematic review, all validated tools used for the prediction of patient-reported outcome measures (PROMs) in patients being treated with radiation therapy for prostate cancer, and provide a comparative summary of accuracy and generalizability. METHODS AND MATERIALS: PubMed and EMBASE were searched from July 2007. Title/abstract screening, full text review, and critical appraisal were undertaken by 2 reviewers, whereas data extraction was performed by a single reviewer. Eligible articles had to provide a summary measure of accuracy and undertake internal or external validation. Tools were recommended for clinical implementation if they had been externally validated and found to have accuracy ≥70%. RESULTS: The search strategy identified 3839 potential studies, of which 236 progressed to full text review and 22 were included. From these studies, 50 tools predicted gastrointestinal/rectal symptoms, 29 tools predicted genitourinary symptoms, 4 tools predicted erectile dysfunction, and no tools predicted quality of life. For patients treated with external beam radiation therapy, 3 tools could be recommended for the prediction of rectal toxicity, gastrointestinal toxicity, and erectile dysfunction. For patients treated with brachytherapy, 2 tools could be recommended for the prediction of urinary retention and erectile dysfunction. CONCLUSIONS: A large number of tools for the prediction of PROMs in prostate cancer patients treated with radiation therapy have been developed. Only a small minority are accurate and have been shown to be generalizable through external validation. This review provides an accessible catalogue of tools that are ready for clinical implementation as well as which should be prioritized for validation.
[Mh] Termos MeSH primário: Disfunção Erétil/etiologia
Gastroenteropatias/etiologia
Medidas de Resultados Relatados pelo Paciente
Neoplasias da Próstata/radioterapia
Retenção Urinária/etiologia
[Mh] Termos MeSH secundário: Idoso
Braquiterapia/efeitos adversos
Coleta de Dados/métodos
Seres Humanos
Masculino
Prognóstico
Estudos Prospectivos
Neoplasias da Próstata/patologia
Qualidade de Vida
Reprodutibilidade dos Testes
Estudos Retrospectivos
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  7 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28469106
[Au] Autor:Yao LH; Wang JJ; Shang C; Jiang P; Lin L; Sun HT; Liu L; Liu H; He D; Yang RJ
[Ad] Endereço:Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
[Ti] Título: Dosimetric Study of Biliary Stent Loaded with Radioactive I Seeds.
[So] Source:Chin Med J (Engl);130(9):1093-1099, 2017 May 05.
[Is] ISSN:0366-6999
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A novel radioactive 125I seed-loaded biliary stent has been used for patients with malignant biliary obstruction. However, the dosimetric characteristics of the stents remain unclear. Therefore, we aimed to describe the dosimetry of the stents of different lengths - with different number as well as activities of 125I seeds. METHODS: The radiation dosimetry of three representative radioactive stent models was evaluated using a treatment planning system (TPS), thermoluminescent dosimeter (TLD) measurements, and Monte Carlo (MC) simulations. In the process of TPS calculation and TLD measurement, two different water-equivalent phantoms were designed to obtain cumulative radial dose distribution. Calibration procedures using TLD in the designed phantom were also conducted. MC simulations were performed using the Monte Carlo N-Particle eXtended version 2.5 general purpose code to calculate the radioactive stent's three-dimensional dose rate distribution in liquid water. Analysis of covariance was used to examine the factors influencing radial dose distribution of the radioactive stent. RESULTS: The maximum reduction in cumulative radial dose was 26% when the seed activity changed from 0.5 mCi to 0.4 mCi for the same length of radioactive stents. The TLD's dose response in the range of 0-10 mGy irradiation by 137Cs γ-ray was linear: y = 182225x - 6651.9 (R2=0.99152; y is the irradiation dose in mGy, x is the TLDs' reading in nC). When TLDs were irradiated by different energy radiation sources to a dose of 1 mGy, reading of TLDs was different. Doses at a distance of 0.1 cm from the three stents' surface simulated by MC were 79, 93, and 97 Gy. CONCLUSIONS: TPS calculation, TLD measurement, and MC simulation were performed and were found to be in good agreement. Although the whole experiment was conducted in water-equivalent phantom, data in our evaluation may provide a theoretical basis for dosimetry for the clinical application.
[Mh] Termos MeSH primário: Dosimetria Termoluminescente/métodos
[Mh] Termos MeSH secundário: Braquiterapia/métodos
Simulação por Computador
Seres Humanos
Método de Monte Carlo
Radiometria/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.4103/0366-6999.204936


  8 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384971
[Au] Autor:Lv WF; Lu D; Xiao JK; Mukhiya G; Tan ZX; Cheng DL; Zhou CZ; Zhang XM; Zhang ZF; Hou CL
[Ad] Endereço:Department of Interventional Radiology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
[Ti] Título:The side effects and complications of percutaneous iodine-125 seeds implantation under CT-guide for patients with advanced pancreatic cancer.
[So] Source:Medicine (Baltimore);96(52):e9535, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The present study investigates the side effects and complications of computed tomography (CT)-guided percutaneous iodine-125 (I-125) seeds implantation for advanced pancreatic cancer. METHODS: The clinical data were retrospectively analyzed for patients treated with implantation of I-125 seeds under CT-guide in our hospital from May 2010 to April 2015. The side effects and complications were collected and their possible reasons were analyzed. RESULTS: A total of 78 patients were enrolled. The side effects were categorized as fever in 29 cases (37.18%), abdominal pain in 26 cases (33.33%), nausea and vomiting in 9 cases (11.54%), diarrhea in 5 cases (6.41%), and constipation in 4 cases (5.13%). Complications were composed of pancreatitis in 9 cases (11.54%), infection in 5 cases (6.41%), seed migration in 2 cases (2.56%), intestinal perforation in 1 case (1.28%), and intestinal obstruction in 1 case. The incidence of complication was 23.08% (18/78). The difference in incidence of complication was statistically significant between patients implanted with ≤27 seeds and those with >27 seeds (P = .032). CONCLUSION: The side effects and complications frequently occur in implantation of I-125 seeds for patients with advanced pancreatic cancer. More concern should be given to the patients treated by this technique.
[Mh] Termos MeSH primário: Braquiterapia/efeitos adversos
Braquiterapia/métodos
Radioisótopos do Iodo/uso terapêutico
Neoplasias Pancreáticas/radioterapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Radiografia Intervencionista
Estudos Retrospectivos
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Iodine Radioisotopes); 0 (Iodine-125)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009535


  9 / 17709 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29420985
[Au] Autor:Ménard C; Paulson E; Nyholm T; McLaughlin P; Liney G; Dirix P; van der Heide UA
[Ad] Endereço:Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis, Room 11.442, Montréal, QC H2X 0A9, Canada; TECHNA Institute, University of Toronto, 124-100 College Street, Toronto, ON M5G 1L5, Canada. Electronic address: Cynthia.Menard@UMontreal.ca.
[Ti] Título:Role of Prostate MR Imaging in Radiation Oncology.
[So] Source:Radiol Clin North Am;56(2):319-325, 2018 Mar.
[Is] ISSN:1557-8275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of prostate MR imaging in radiotherapy continues to evolve. This article describes its current application in the selection of treatment regimens, integration in treatment planning or simulation, and assessment of response. An expert consensus statement from the annual MR in RT symposium is presented, as a list of 21 key quality indicators for the practice of MR imaging simulation in prostate cancer. Although imaging requirements generally follow PIRADSv2 guidelines, additional requirements specific to radiotherapy planning are described. MR imaging-only workflows and MR imaging-guided treatment systems are expected to replace conventional computed tomography-based practice, further adding specific requirements for MR imaging in radiotherapy.
[Mh] Termos MeSH primário: Braquiterapia/métodos
Imagem por Ressonância Magnética/métodos
Neoplasias da Próstata/diagnóstico por imagem
Neoplasias da Próstata/radioterapia
Radioterapia (Especialidade)/métodos
Planejamento da Radioterapia Assistida por Computador/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Próstata/diagnóstico por imagem
Próstata/patologia
Neoplasias da Próstata/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE


  10 / 17709 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390560
[Au] Autor:Wang G; Zhao Z; Wei J; Yang J
[Ad] Endereço:Department of Ultrasound.
[Ti] Título:Fibromyxoid sarcoma in the retroperitoneum: A case report.
[So] Source:Medicine (Baltimore);96(51):e9409, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Low-grade fibromyxoid sarcoma (LGFMS) is a pathological type of fibrosing fibrosarcoma that appears as a distinctive soft tissue masse with bland histological features. It is mostly located in the deep soft tissues of the extremities. Computed tomography (CT) plays an important role in diagnosing fibrosing fibrosarcoma in the abdomen. To date, several studies in the literature have reported on CT features of LGFMS. PATIENT CONCERNS AND DIAGNOSES: We report another case of LGFMS, which presented with certain unique CT feature. The anterolateral region and the wall of the cystic nodules showed gradual enhancement and several nourishing vessels were seen after contrast administration. These imaging features were consistent with the histologic findings of LGFMS. INTERVENTIONS AND OUTCOMES: The patient underwent tumorectomy and implantation of radioactive implants. Two years after the operation, 1 metastasis mass occur in the right psoas major. LESSONS: These CT features in LGFMS may be useful to assess the histological characteristics of LGFMS to facilitate preoperative diagnosis in the clinical setting and provide the supplemental imaging knowledge for future studies.
[Mh] Termos MeSH primário: Fibrossarcoma/diagnóstico por imagem
Neoplasias Retroperitoneais/diagnóstico por imagem
[Mh] Termos MeSH secundário: Braquiterapia
Terapia Combinada
Fibrossarcoma/patologia
Fibrossarcoma/terapia
Seres Humanos
Hidroxietilrutosídeo
Masculino
Meia-Idade
Neoplasias Retroperitoneais/patologia
Neoplasias Retroperitoneais/terapia
Espaço Retroperitoneal/diagnóstico por imagem
Espaço Retroperitoneal/patologia
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydroxyethylrutoside)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009409



página 1 de 1771 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde